{"prompt": "['MC1575', '73', 'Amendment 2', 'Oral Antihypertensive Medications for patients with non-secretory tumors', 'Agent', 'Initial', 'Intermediate', 'Maximum', 'Hepatic', 'class', 'Agent', 'dose', 'dose', 'dose', 'metabolism', 'Dihydro-', 'nifedipine XL', '30 mg daily', '60 mg daily', '90 mg daily', 'CYP 3A4 substrate', 'pyridine', 'Calcium-', 'amlodipine', '2.5 mg daily', '5 mg daily', '10 mg daily', 'CYP 3A4 substrate', 'Channel', 'Blockers', 'CYP 3A4 substrate', 'felodipine', '2.5 mg daily', '5 mg daily', '10 mg daily', '(DHP CCB)', 'and inhibitor', '25 mg', '50 mg', 'metoprolol', '100 mg', 'CYP 2D6 substrate', 'twice daily', 'twice daily', 'twice daily', 'Selective', 'atenolol', '25 mg daily', '50 mg daily', '100 mg daily', 'No', '\u00df Blockers', 'acebutolol', '100 mg', '200-300 mg', '400 mg', 'Yes (CYP450', '(BB)', 'twice daily', 'twice daily', 'twice daily', 'unknown)', 'Yes (CYP450', 'bisoprolol', '2.5 mg daily', '5-10 mg daily', '20 mg daily', 'unknown)', 'captopril', '12.5 mg 3x', '25 mg 3x daily', '50 mg 3x daily', 'CYP 2D6 substrate', 'daily', 'enalapril', '5 mg daily', '10-20 mg daily', '40 mg daily', 'CYP 3A4 substrate', 'Yes (CYP450', 'Angiotensin', 'ramipril', '2.5 mg daily', '5 mg daily', '10 mg daily', 'unknown)', 'Converting', 'Enzyme', 'lisinopril', '5 mg daily', '10-20 mg daily', '40 mg daily', 'No', 'Inhibitors', '(ACEIs)', 'Yes (CYP450', 'fosinopril', '10 mg daily', '20 mg daily', '40 mg daily', 'unknown)', 'Rarely used:', 'Yes, but not', '4 mg daily', 'none', 'perindopril', '8 mg daily', 'CYP450', 'Rarely used:', 'quinapril', '10 mg daily', '20 mg daily', '40 mg daily', 'No', 'losartan', '25 mg daily', '50 mg daily', '100 mg daily', 'CYP 3A4 substrate', 'candesartan', '4 mg daily', '8-16 mg daily', '32 mg daily', 'CYP 2C9 substrate', 'Angiotensin II', 'irbesartan', 'Receptor', '75 mg daily', '150 mg daily', '300 mg daily', 'CYP 2C9 substrate', 'Blockers', 'Yes, but not', '(ARBs)', 'telmisartan', '40 mg daily', 'none', '80 mg daily', 'CYP450', 'Yes, but not', 'valsartan', '80 mg daily', 'none', '160 mg daily', 'CYP450', 'a and \u00df', 'labetolol', '100 mg twice', '200 mg twice', '400 mg twice', 'CYP 2D6 substrate', 'Blocker', 'daily', 'daily', 'daily', 'and inhibitor', 'Protocol Version Date:16Aug2018']['MC1575', '74', 'Amendment 2', 'D2. Management of Lenvatinib-Induced Hypertension: Secretory Tumors', 'All patients with secretory pheochromocytoma: or paragangliomas are required to: 1) be evaluated in', 'consultation, and followed by, a hypertension specialization with experience in the management of', 'hypertension in the setting of catecholamine-secreting tumors (usually an endocrinologist, nephrologist,', 'or a cardiologist), and 2) receive a. and -adrenergic blockade for at least 7-14 days prior to initiation of', 'lenvatinib (see below for guidelines regarding proper a- and \u00df-blockade). The hypertension specialist of', 'record for each patient should be committed to following the patient during the clinical study on an as', 'needed basis.', 'Recommended Hypertension Monitoring and Management for', 'Patients with Catecholamine-Secreting Tumors (BP in mmHg)', '(CTCAE SOC Vascular Disorders/Hypertension)', 'Blood', 'Grade', 'Antihypertensive', 'Pressure', 'Lenvatinib', '(CTCAE v4)', 'Therapy', 'Monitoring', 'Dose Modification', 'Persistent*', 'Standard a- and -adrenergic', 'Standard', 'No Change', 'Grade 1', 'blockade', 'Pre-hypertension', 'Systolic 120-139', 'Diastolic 80-90', 'Persistent* Grade', 'Step 1) Advance dose of a.', 'BP should be', 'No change except as', '2- Moderate', 'adrenergic blocker until BP is', 'monitored as', 'described in Step 4', 'Systolic 140-159', 'controlled or at max dose of Rx.', 'recommended', 'Diastolic 90-99', 'The -adrenergic blocker dosage', 'by the', 'should be advanced for a target', 'treating', 'Protocol-specific', 'heart rate of less than 80 bpm.', 'physician and', 'guidance', \"patient's\", 'supersedes any', 'Step 2) If BP still not controlled,', 'identified', 'other management', 'add another anti-hypertensive Rx', 'hypertension', 'guidelines.', '(usually best a calcium channel', 'specialist', 'blocker such as amlodipine), in', \"conjunction with the patient's\", 'identified hypertension specialist,', 'increasing dosage of this drug as', 'described in step 1 or as suggested', \"by patient's identified\", 'hypertension specialist.', 'Step 3) If BP is still not', 'controlled, consider either 1 dose', 'reduction of lenvatinib or', 'withholding lenvatinib until BP is', 'better controlled.', 'NOTE: Stopping or reducing the', 'dose of lenvatinib is expected to', 'cause a decrease in BP. The', 'treating physician must therefore', 'monitor the subject for', 'hypotension and adjust the', 'number and dose of', 'antihypertensive medication(s)', 'accordingly', 'Protocol Version Date:16Aug2018']\n\n###\n\n", "completion": "END"}